Loading provider…
Loading provider…
Hematology & Oncology Physician in Placerville, CA
NPI: 1326202540Primary Practice Location
Marshall Medical Center
1100 Marshall Way, Placerville, CA
Primary Employer
Marshall Medical Center
marshallmedical.org
HQ Phone
Get MD Rashmi's Phone Numberphone_androidMobile
Get MD Rashmi's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2013 - 2026
MO State Medical License
2010 - 2014
IL State Medical License
2007 - 2007

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Carle Foundation Hospital
Residency • Internal Medicine
2004 - 2007
Western Kentucky University
MS • Biology
2001 - 2004
Sri Devaraj URS Medical College
Medical School
Until 1999
Indiana University School Of Medicine
medicine.iu.edu
Fellowship • Hematology and Medical Oncology
2008 - 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 311 | 743 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 118 | 295 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 50 | 51 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 42 | 42 |
| 5 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 25 | 27 |
MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
Authors: Daniel Kapp, Tuyen Kiet, Daniela Matei
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Authors: Jeanne Schilder, Daniela Matei
Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101
Authors: E. Gabriela Chiorean, Rashmi Ramasubbaiah, Menggang Yu, Joel Picus, Jose A. Bufill